Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
<div><p>Total CSF α-synuclein (t-α-syn), phosphorylated α-syn (pS129-α-syn) and α-syn oligomers (o-α-syn) have been studied as candidate biomarkers for synucleinopathies, with suboptimal specificity and sensitivity in the differentiation from healthy controls. Studies of α-syn species in...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513515276992512 |
|---|---|
| author | Vasilios C. Constantinides (18595828) |
| author2 | Nour K. Majbour (8809316) George P. Paraskevas (18595831) Ilham Abdi (18394764) Bared Safieh-Garabedian (3554684) Leonidas Stefanis (264252) Omar M. El-Agnaf (3172641) Elisabeth Kapaki (489534) |
| author2_role | author author author author author author author |
| author_facet | Vasilios C. Constantinides (18595828) Nour K. Majbour (8809316) George P. Paraskevas (18595831) Ilham Abdi (18394764) Bared Safieh-Garabedian (3554684) Leonidas Stefanis (264252) Omar M. El-Agnaf (3172641) Elisabeth Kapaki (489534) |
| author_role | author |
| dc.creator.none.fl_str_mv | Vasilios C. Constantinides (18595828) Nour K. Majbour (8809316) George P. Paraskevas (18595831) Ilham Abdi (18394764) Bared Safieh-Garabedian (3554684) Leonidas Stefanis (264252) Omar M. El-Agnaf (3172641) Elisabeth Kapaki (489534) |
| dc.date.none.fl_str_mv | 2021-01-17T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/brainsci11010119 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Cerebrospinal_Fluid_-Synuclein_Species_in_Cognitive_and_Movements_Disorders/25878295 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Neurosciences α-synuclein cerebrospinal fluid biomarkers tau proteins beta amyloid parkinsonism dementia neurodegenerative disorders |
| dc.title.none.fl_str_mv | Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <div><p>Total CSF α-synuclein (t-α-syn), phosphorylated α-syn (pS129-α-syn) and α-syn oligomers (o-α-syn) have been studied as candidate biomarkers for synucleinopathies, with suboptimal specificity and sensitivity in the differentiation from healthy controls. Studies of α-syn species in patients with other underlying pathologies are lacking. The aim of this study was to investigate possible alterations in CSF α-syn species in a cohort of patients with diverse underlying pathologies. A total of 135 patients were included, comprising Parkinson’s disease (PD; n = 13), multiple system atrophy (MSA; n = 9), progressive supranuclear palsy (PSP; n = 13), corticobasal degeneration (CBD; n = 9), Alzheimer’s disease (AD; n = 51), frontotemporal degeneration (FTD; n = 26) and vascular dementia patients (VD; n = 14). PD patients exhibited higher pS129-α-syn/α-syn ratios compared to FTD (p = 0.045), after exclusion of samples with CSF blood contamination. When comparing movement disorders (i.e., MSA vs. PD vs. PSP vs. CBD), MSA patients had lower α-syn levels compared to CBD (p = 0.024). Patients with a synucleinopathy (PD and MSA) exhibited lower t-α-syn levels (p = 0.002; cut-off value: ≤865 pg/mL; sensitivity: 95%, specificity: 69%) and higher pS129-/t-α-syn ratios (p = 0.020; cut-off value: ≥0.122; sensitivity: 71%, specificity: 77%) compared to patients with tauopathies (PSP and CBD). There are no significant α-syn species alterations in non-synucleinopathies.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Brain Sciences<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/brainsci11010119" target="_blank">https://dx.doi.org/10.3390/brainsci11010119</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_c922ba43c3d5dfb631b485f616fe8b04 |
| identifier_str_mv | 10.3390/brainsci11010119 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25878295 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements DisordersVasilios C. Constantinides (18595828)Nour K. Majbour (8809316)George P. Paraskevas (18595831)Ilham Abdi (18394764)Bared Safieh-Garabedian (3554684)Leonidas Stefanis (264252)Omar M. El-Agnaf (3172641)Elisabeth Kapaki (489534)Biomedical and clinical sciencesNeurosciencesα-synucleincerebrospinal fluidbiomarkerstau proteinsbeta amyloidparkinsonismdementianeurodegenerative disorders<div><p>Total CSF α-synuclein (t-α-syn), phosphorylated α-syn (pS129-α-syn) and α-syn oligomers (o-α-syn) have been studied as candidate biomarkers for synucleinopathies, with suboptimal specificity and sensitivity in the differentiation from healthy controls. Studies of α-syn species in patients with other underlying pathologies are lacking. The aim of this study was to investigate possible alterations in CSF α-syn species in a cohort of patients with diverse underlying pathologies. A total of 135 patients were included, comprising Parkinson’s disease (PD; n = 13), multiple system atrophy (MSA; n = 9), progressive supranuclear palsy (PSP; n = 13), corticobasal degeneration (CBD; n = 9), Alzheimer’s disease (AD; n = 51), frontotemporal degeneration (FTD; n = 26) and vascular dementia patients (VD; n = 14). PD patients exhibited higher pS129-α-syn/α-syn ratios compared to FTD (p = 0.045), after exclusion of samples with CSF blood contamination. When comparing movement disorders (i.e., MSA vs. PD vs. PSP vs. CBD), MSA patients had lower α-syn levels compared to CBD (p = 0.024). Patients with a synucleinopathy (PD and MSA) exhibited lower t-α-syn levels (p = 0.002; cut-off value: ≤865 pg/mL; sensitivity: 95%, specificity: 69%) and higher pS129-/t-α-syn ratios (p = 0.020; cut-off value: ≥0.122; sensitivity: 71%, specificity: 77%) compared to patients with tauopathies (PSP and CBD). There are no significant α-syn species alterations in non-synucleinopathies.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Brain Sciences<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/brainsci11010119" target="_blank">https://dx.doi.org/10.3390/brainsci11010119</a></p>2021-01-17T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/brainsci11010119https://figshare.com/articles/journal_contribution/Cerebrospinal_Fluid_-Synuclein_Species_in_Cognitive_and_Movements_Disorders/25878295CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/258782952021-01-17T03:00:00Z |
| spellingShingle | Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders Vasilios C. Constantinides (18595828) Biomedical and clinical sciences Neurosciences α-synuclein cerebrospinal fluid biomarkers tau proteins beta amyloid parkinsonism dementia neurodegenerative disorders |
| status_str | publishedVersion |
| title | Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders |
| title_full | Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders |
| title_fullStr | Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders |
| title_full_unstemmed | Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders |
| title_short | Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders |
| title_sort | Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders |
| topic | Biomedical and clinical sciences Neurosciences α-synuclein cerebrospinal fluid biomarkers tau proteins beta amyloid parkinsonism dementia neurodegenerative disorders |